Adjunctive LDL-Lowering Therapies

Non-statin LDL-lowering therapy use was rare despite statin barriers and suboptimal LDL control. Only one patient used a PCSK9 inhibitor, and no patients received bempedoic acid. Ezetimibe was prescribed to 4.1% of patients. Among patients with statin intolerance or refusal, alternative LDL-lowering therapy use was very low.